Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2003 3
2004 2
2005 1
2006 2
2007 6
2008 6
2009 8
2010 17
2011 19
2012 17
2013 27
2014 39
2015 39
2016 41
2017 43
2018 47
2019 41
2020 52
2021 48
2022 38
2023 57
2024 52

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

527 results

Results by year

Filters applied: . Clear all
Page 1
Semaglutide for the treatment of overweight and obesity: A review.
Bergmann NC, Davies MJ, Lingvay I, Knop FK. Bergmann NC, et al. Among authors: knop fk. Diabetes Obes Metab. 2023 Jan;25(1):18-35. doi: 10.1111/dom.14863. Epub 2022 Oct 18. Diabetes Obes Metab. 2023. PMID: 36254579 Free PMC article. Review.
Glucagon Receptor Signaling and Glucagon Resistance.
Janah L, Kjeldsen S, Galsgaard KD, Winther-Sørensen M, Stojanovska E, Pedersen J, Knop FK, Holst JJ, Wewer Albrechtsen NJ. Janah L, et al. Among authors: knop fk. Int J Mol Sci. 2019 Jul 5;20(13):3314. doi: 10.3390/ijms20133314. Int J Mol Sci. 2019. PMID: 31284506 Free PMC article. Review.
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.
Frias JP, Deenadayalan S, Erichsen L, Knop FK, Lingvay I, Macura S, Mathieu C, Pedersen SD, Davies M. Frias JP, et al. Among authors: knop fk. Lancet. 2023 Aug 26;402(10403):720-730. doi: 10.1016/S0140-6736(23)01163-7. Epub 2023 Jun 23. Lancet. 2023. PMID: 37364590 Clinical Trial.
100 years of glucagon and 100 more.
Wewer Albrechtsen NJ, Holst JJ, Cherrington AD, Finan B, Gluud LL, Dean ED, Campbell JE, Bloom SR, Tan TM, Knop FK, Müller TD. Wewer Albrechtsen NJ, et al. Among authors: knop fk. Diabetologia. 2023 Aug;66(8):1378-1394. doi: 10.1007/s00125-023-05947-y. Epub 2023 Jun 27. Diabetologia. 2023. PMID: 37367959 Review.
Glucagon-like peptide 1 in health and disease.
Andersen A, Lund A, Knop FK, Vilsbøll T. Andersen A, et al. Among authors: knop fk. Nat Rev Endocrinol. 2018 Jul;14(7):390-403. doi: 10.1038/s41574-018-0016-2. Nat Rev Endocrinol. 2018. PMID: 29728598 Review.
Editorial: Proglucagon-Derived Peptides.
Flatt PR, Knop FK, Tarasov AI. Flatt PR, et al. Among authors: knop fk. Front Endocrinol (Lausanne). 2021 Nov 11;12:776871. doi: 10.3389/fendo.2021.776871. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34858346 Free PMC article. No abstract available.
FGF21 suppresses alcohol consumption through an amygdalo-striatal circuit.
Flippo KH, Trammell SAJ, Gillum MP, Aklan I, Perez MB, Yavuz Y, Smith NK, Jensen-Cody SO, Zhou B, Claflin KE, Beierschmitt A, Fink-Jensen A, Knop FK, Palmour RM, Grueter BA, Atasoy D, Potthoff MJ. Flippo KH, et al. Among authors: knop fk. Cell Metab. 2022 Feb 1;34(2):317-328.e6. doi: 10.1016/j.cmet.2021.12.024. Cell Metab. 2022. PMID: 35108517 Free PMC article.
527 results